Sera of camelids contain both conventional heterotetrameric antibodies and unique functional heavy (H)-chain antibodies (HCAbs). The H chain of these homodimeric antibodies consists of one antigen-binding domain, the VHH, and two constant domains. HCAbs fail to incorporate light (L) chains owing to the deletion of the first constant domain and a reshaped surface at the VHH side, which normally associates with L chains in conventional antibodies. The genetic elements composing HCAbs have been identified, but the in vivo generation of these antibodies from their dedicated genes into antigen-specific and affinity-matured bona fide antibodies remains largely underinvestigated. However, the facile identification of antigen-specific VHHs and their beneficial biochemical and economic properties (size, affinity, specificity, stability, production cost) supported by multiple crystal structures have encouraged antibody engineering of these single-domain antibodies for use as a research tool and in biotechnology and medicine.
Nanobodies: Natural Single-Domain Antibodies
INTRODUCTION
The overall structure of immunoglobulin-γ (IgG) antibodies assembled from two identical heavy (H)-chain and two identical light (L)-chain polypeptides is well established and highly conserved in mammals (Figure 1 ) (1) . The L chain of these immunoglobulins comprises two domains, whereas the H chain folds into four domains. The sequence of the N-terminal domain of the H and L polypeptides' chains varies between antibodies (designated as variable domains, i.e., VH and VL).
The paired VH-VL domains constitute the variable fragment (Fv) that recognizes the antigen. The remaining H and L sequences are more conserved (abbreviated as CH and CL, respectively). The two last CH regions are important for recruitment of immune cells (e.g., macrophages and natural killer cells) or for effector functions (e.g., complement activation).
One notorious exception to this conventional mammalian IgG structure is found in sera of Camelidae (2) . In addition to the conventional heterotetrameric antibodies, these sera possess special IgG antibodies. IgG antibodies, known as heavy-chain antibodies (HCAbs), are devoid of the L chain polypeptide and are unique because they lack the first constant domain (CH1) (Figure 1) . At its N-terminal region, the H chain of the homodimeric protein contains a dedicated variable domain, referred to as VHH, which serves to associate with its cognate antigen. The VHH in an HCAb is the structural and functional equivalent of the Fab fragment (antigen-binding fragment) of conventional antibodies (Figure 1) .
The biological family Camelidae comprises camels (one-humped Camelus dromedarius and two-humped Camelus bactrianus), llama's (Lama glama and Lama guanicoe), and vicugna's (Vicugna vicugna and Vicugna pacos). Camelidae is the only extant family in the suborder Tylopoda, which constitutes together with Ruminantia (bovine, goat, sheep, antelope, and others) and Suiformes (pig and hippopotami) the order of Artiodactyla. Although all camelids have HCAbs in their sera, other artiodactyls such as Suiformes and Ruminantia do not have such functional HCAbs. However, HCAbs resulting from a genetic deletion of significant parts of the VH and CH1 regions have been reported to occur in sera of humans with a pathological disorder (3, 4) or in mouse hybridoma (5 of a conventional CH1 also occur in nurse shark, wobbegong, and perhaps spotted ratfish (6) . These Ig-NAR ancestral antibodies have a variable domain, known as V-NAR, for antigen recognition. Although the variable (V) sequences of Ig-NARs and those of camel HCAbs are quite diverse, they show a surprising structural and functional convergent evolution (7) .
The antigen-binding fragment of an HCAb, containing one single variable domain, allows straightforward identification of antigenbinding VHHs after immunizing a camelid, cloning the VHH repertoire of B cells circulating in blood, and panning by phage display (8) . The recombinant antigen-specific, singledomain VHH with dimensions in the nanometer range is also known as a nanobody (Nb) or single-domain antibody (sdAb). In this review, we summarize the main structural characteristics of HCAbs and the VHH domain, as well as provide an update of the possible generation mechanisms of HCAbs in Camelidae. Finally, we review the biochemical properties of the Nbs that form the basis for a wide variety Schematic representation of naturally occurring antibodies in sera of camelids: conventional antibodies (IgG1) containing two light (L) chains (the VL and CL domains) and two heavy (H) chains (composed of the VH, CH1, hinge, and CH2 and CH3 domains) and two types of homodimeric heavy-chain antibodies (HCAbs), IgG2 and IgG3, which comprise only H chains; each H chain contains a VHH, hinge, and CH2 and CH3 domains. The hinge of the IgG2 fraction is longer than that of the IgG3 type. As indicated in the figure, the CH2 and CH3 domains form the Fc part. In IgG1, the first two domains of the H chain and the L chain form the Fab fragment. The smallest intact functional antigen-binding fragment that can be generated from conventional antibodies, consisting of a VH-VL pair and linked by an oligopeptide, is known as scFv (top right). The smallest intact functional antigen-binding fragment of HCAbs is the single-domain VHH, also known as a nanobody (Nb) (bottom right). Abbreviations: CH, constant domain of immunoglobulin H chain; Fab, antigen-binding fragment; Fc, crystallizable fragment; scFv, single-chain variable fragment.
and an increasing number of routine and innovative applications in research, biotechnology, and medicine.
STRUCTURAL FEATURES OF HEAVY-CHAIN ANTIBODIES AND NANOBODIES

Heavy-Chain Antibody Subisotypes in Sera of Camelids
The absence of L chains in the IgG and lack of the CH1 in the H chain are key characteristics of camelid HCAbs. Consequently, their smaller size with a mol wt of 90,000 rather than 150,000 for conventional antibodies and their more compact architecture might be better adapted to access hidden targets. Conversely, the shorter distance between the two paratopes within one HCAb might compromise their capacity to cross-link antigens, although it has been speculated that the long IgG2 hinge containing Pro-Gln repeats might form an extended spacer that structurally replaces the CH1 region (Figure 1 ) (2) . The percentage of HCAbs and conventional IgG in the sera of camelids is variable: In camels, it might reach 50-80%, whereas in South American camelid species, it totals up to 10-25% (9) . Such a significant proportion is a testament for the importance of HCAbs in the immune protection of the camelid.
Several IgG subisotypes devoid of L chains circulate in the bloodstream of camelids, although the exact number remains controversial owing to the difficulties of purifying subisotypes to homogeneity and of distinguishing subisotypes from allotypes. Nevertheless, the homodimeric and heterotetrameric antibodies are easily separated by differential affinity chromatography on protein G and protein A, where conventional antibodies are eluted at a lower pH from protein G columns (2, 10) . The dromedary IgG fraction that is not retained on protein G is adsorbed on protein A, and careful pH-controlled elution yields two distinct HCAb-IgG2 fractions, named IgG2a and IgG2b (10) . The investigators show that fractions from these adsorbents might still contain several subisotypes. Monoclonal antibodies raised against the IgGs of different protein A/G fractions and used to screen llama sera immunoglobulins confirmed the presence of two isotypes of conventional IgGs as well as possibly three and two subisotypes within the IgG2 and IgG3 fractions, respectively (11) (12) (13) .
The analysis of IgG cDNA from dromedary B lymphocytes reveals the occurrence of two IgG subisotypes for conventional antibodies, whereas HCAbs include multiple IgG subisotypes (14) . The various cDNA sequences still need to be matched to the subisotypes (or allotypes) as obtained from protein A and protein G chromatography or anti-isotype monoclonal antibodies. Despite the uncertainty of the exact number of IgG subisotypes circulating in camelid blood, the numbers are within the range of IgGs in other artiodactyls. Three IgG isotypes have been identified from bovine (15) , whereas pigs contain six IgG isotypes that cannot be separated by protein A and/or protein G chromatography (16) .
Studies of human and mouse antibodies demonstrate a clear division of labor among IgG subisotypes. Although knowledge of the exact roles and functions of the various camelid IgG subisotypes is still in its infancy, an infected or vaccinated animal raises an immune response in the three isotype fractions (to various extents in different animals, depending on the actual immunogen). Remarkably, the llama IgG1 and IgG3 neutralize West Nile virus, whereas IgG2 seems less effective in this respect (17) . However, the same study indicated that IgGs from all three isotypes bind to the surface of monocytes and macrophages, indicating that they are able to recruit immune cells.
Structure of VHH
The sequence variability within V domains is localized in three hypervariable (HV) regions surrounded by more conserved framework (FR) regions (Figure 2) (1). The folded V domain comprises nine β-strands (A-B-C-C -C -D-E-F-G), organized in a four-stranded β-sheet and a five-stranded β-sheet, connected by loops and by a conserved disulfide bond between Cys23 and Cys94, packed against a conserved Trp. In this architecture, the HV regions are located in the loops H1 to H3 that connect the B-C, the C -C , and the F-G strands, respectively, and that cluster at the N-terminal end of the domain forming a continuous surface, which is complementary to the surface of the epitope, hence its name complementarity-determining region (CDR). Although the sequence within the loop is HV, the length variation is limited except for the H3 loop. Surprisingly the Cα positions within the H1 and H2 loops occupy restrictive locations. Apparently only a few, so-called, canonical loop structures have been observed in human or mouse VH structures, and even the number of loop architecture combinations
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CH2 CH3 is restricted (18) . Hence, the loop length and presence of key residues within the loop predict its actual architecture. In a conventional antibody, the three HV loops of the VH and the three HV loops of the VL are juxtaposed and provide a platform of some 600-900Å 2 (the exact interacting surface depends on the size of the loop and its amino acids, as well as on the algorithm used for the calculation). Overall, the paratope of conventional antibodies forms a cavity, groove, or a flat surface (with minor undulations of individual amino acid side chains sticking out), and these architectures have been linked to the recognition of small molecules, linear peptides, and larger antigens (such as proteins), respectively (19) .
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Alignment of VHH amino acid sequences immediately indicates that the structural organization of the FR and HV regions is similar to the VH, with a few notable differences in framework 2 (FR2) and in CDRs. Within FR2, highly conserved hydrophobic amino acids (Val47, Gly49, Leu50, Trp52) that normally participate in the interaction with the VL domain (20) are replaced in a VHH by smaller and/or hydrophilic amino acids (mostly Phe42, Glu49, Arg50, Gly52) (Figure 2 ) (21) (22) (23) (24) . Reshaping this VL side of the domain abrogates any VL interaction and assists in the nonstickiness of the domain in absence of a VL. Indeed, it has been shown that a mouse VH in absence of the VL partner is sticky, and the substitution of FR2 to mimic the amino acids of camelid VHH renders the camelized domain more soluble (25). Conversely, the substitution of the amino acids at these positions in a VHH to mimic a human VH leads to the dimerization of the humanized VHH, where one humanized VHH structurally replaces the VL domain as in a VH-VL pairing within conventional antibodies (26). However, minor deviations were observed in the actual dimerization motif (27). Remarkably, in an effort to engineer an autonomous V domain of the VH from a singlechain variable fragment (scFv), mutations were introduced in the former VL side of the human VH and were screened for the best solution (in terms of expression, monomeric state, and thermal stability) (28). The amino acid position and nature of the optimal substitutions were equivalent but not identical to what nature evolved in camelid VHHs. This finding indicated that nature chose one out of a number of possibilities to form an autonomous functioning VHH. Although the V-NAR and VHH sequences are very diverse, the increased frequency of polar and charged residues at the VL side of the domain supports convergent evolution in this region between these two single antigen-binding domains (29).
The second difference between VH and VHH is observed in the HV loops: Because the VHH in an HCAb acts autonomously (independently from the presence of a VL, as seen in conventional antibodies), the antigen is recognized by only three loops instead of six loops. To provide a sufficiently large antigeninteracting surface of 600-800Å 2 (30), the loops are longer in a VHH than in a VH of a conventional antibody. This was apparent from the sequence alignments that indicated an enlarged HV region in the H1 loop and the presence of an extended H3 loop (Figure 2 ) (31). The enlarged HV loop 1 finds its origin in the germ line genes, whereas the longer H3 loop is probably due to the selection of functional VHH domains after V-D-J recombination. An extended loop implies a larger flexibility, and this is expected to be entropically counterproductive for binding. This issue is solved in camel VHHs by constraining the long loops with a disulfide bond (32). Indeed, many camel VHH sequences contain an extra pair of Cys residues in the H1 and H3 loops, which are known to form an interloop disulfide bond (Figure 2) , evidently restricting the flexibility of the loops in absence of the antigen. Surprisingly in llama VHH, this extra disulfide bond occurs less frequently, but the H3 loop is on average also notably shorter in llama than in dromedary VHH (22) (23) (24) . The interloop disulfide bond in dromedary VHH is mainly formed between the H1 and H3 loops; however, in a small number (∼10%) of VHH, a disulfide bond is also observed between the H3 and the FR2 position 50. Also, shark V-NARs evolved to have equivalent disulfide bonds tethering the antigen-binding loops (33, 34). In llama VHHs, and sporadically in dromedary VHHs as well, we noticed an interloop disulfide bond between the H3 loop and the H2 loop (position 55) (22, 23) . Although the position of the Cys in the H1 loop is restricted at positions 30, 32, or 33 (position 50 in FR2, or position 55 in H2), in the H3 loop, the Cys occurs at nearly all possible positions in the N end, the middle, or the C end of the H3 loop (14) . In a limited number of VHHs, the H3 loop had an extended conformation stretching out from the remainder of the domain (as in the VH of a conventional antibody). This was observed mainly when the VHH had a Tyr at position 42 and a shorter than usual H3 loop length as in a green fluorescent protein (GFP) binder (35). In VHH with Phe42, the long H3 loop adopts a specific conformation, named stretched twisted turn, whereby the base of the loop is twisted, and the tip is folded toward the C strand (the 7 th or 8 th amino acid counting from the C end of the H3 loop approaches the FR2 amino acid at position 52, especially when it is Gly) (36). In this H3 configuration, the Phe42 is shielded from contact with water by the H3 loop ( Figure 2 ). An aromatic core formed by Trp118 (FR4), Tyr93 (FR3), and Phe117 or Tyr117 probably stablizes this H3 loop conformation.
The prolate (rugby ball-shaped) structure of the VHH domain forms a convex paratope surface, which makes it extremely suitable to insert in cavities on the surface of the antigen (30). This type of interaction increases the actual interaction surface of the paratope. The long H3 sequences can form a protruding loop [as in cAb-Lys3 (37)]; however, this seems to be a special case, and the long loop in most Nb structures folds over the FR2 region to form a flat paratope surface (38). As in V-NAR where the HV4 region (loop between the D-E strands) participates actively in antigen recognition, this loop in a VHH is also often close to the antigen. Although there is some increased variability at this position in the domain, its involvement in antigen binding is rather limited. In contrast, the amino acids at the N end of the extended H1 loop are regularly highly involved in antigen recognition (39). Overall, the paratope architecture forms a variety of structures ranging from protruding loops shared with V-NARs (33, 37) to a flat surface (38), and also a cavity as seen for the antihapten binders (40, 41).
DEDICATED HEAVY-CHAIN ANTIBODY GENES
Organization of the H Locus in the Genome of Camelids
The human and mouse H gene locus comprises a sequential organization of multiple V elements, D elements, and JH elements upstream of the constant immunoglobulin genes IGHM, IGHD, IGHG, IGHE, and IGHA, although a variable copy number for each gene per haploid can be found in different animals (42). Likewise, the elements that produce the H chain for conventional antibodies and for HCAb are located in the same locus in the camelid genome (Figure 2) (8, 43) . It is clear that dromedary and the alpaca employ dedicated IGHG genes to produce HCAbs. Thus, some IGHG genes are used exclusively for conventional antibodies, and a different set of IGHG genes will produce HCAbs (44, 45). Compared to the IGHG genes for conventional antibodies, these genes have an identical organization of exons, introns, switch regions, and alternative polyadenylation sites that produce secreted and membrane-bound IgG molecules. Nucleotide sequences for the CH1 exon are embedded; however, they carry a nucleotide G to a point mutation that disrupts the consensus splicing site (GT) at the 5 end of the intron between the CH1-hinge exons and that provokes the elimination of the CH1 region from the mRNA by splicing. Most likely, there are no camel-specific factors required for this unique splicing, as the dromedary IGHG2a gene, complemented with an upstream promoter and rearranged VHH-D-J gene fragment and introduced in an NSO mouse cell line or in a transgenic mouse, is properly spliced and generates functional HCAbs in the culture supernatant or serum, respectively (46, 47).
In contrast, a transgenic mouse with the dromedary-specific CH1 mutation in the human IGHG2 and IGHG3 genes fails to produce functional HCAbs (48). Successful HCAbs could be generated if the entire CH1 exon was deleted from the same genes. This indicates that (unidentified) surrounding nucleotides of the CH1 exon/intron splicing site in the camelid IGHG genes might be essential for proper VHH-hinge splicing. The analysis of dromedary genomic clones further identified the existence of putative IGHG genes for HCAb that were never observed in cDNA sequences and that probably reflect pseudogenes (29).
It seems that the alpaca genome contains only one IGHM gene with a functional CH1 splicing site (43). Also, the cDNA analysis showed that the mRNA with a rearranged VH-D-J and that with a VHH-D-J region maintains the CH1 exon sequences.
Dedicated VHH Genes in the H Locus
The camelid genome also harbors dedicated VHH germ line genes (denoted as IGHVH) interspersed with the VH germ line genes for conventional antibodies (designated as IGHV) (Figure 2) (Figure 2) , it might come as a surprise that the H3 loops of VHHs (formed by the V-D-J junction) are on average longer than those of VHs. The longer CDR3 in VHH domains might be explained in several ways: (a) a higher activity of deoxynucleotidyl transferase during the V-D-J rearrangement, but this is less plausible as it implies that a distinct subset of B cells is predestined to produce HCAbs; (b) a selection at the pre-B-cell receptor stage, a checkpoint to ensure that the V-D-J rearrangement produces a properly folded V domain; or (c) a selection on functionality where it is hypothesized that those VHH domains with shorter H3 loops will most likely have a too small putative antigen-binding surface, which makes it less likely that such B cells will bind to antigen and be expanded during an immune response. Interestingly, IGHVH genes also differ from IGHV genes because of the presence of a Cys codon in the CDR1 region (or position 50 in the FR2 region) in dromedary (31) or Cys55 in alpaca VHH (43). The second Cys codon in the H3 loop is introduced during the V-D-J recombination or afterward by somatic hypermutation. Obviously, a B cell where the V-D-J recombination product contains only one single Cys (apart from the conserved Cys23-Cys94 pair) will be counterselected if it does not manage to replace this Cys by mutating the Cys codon or to introduce a second Cys codon at a suitable position to form a cystine. Indeed the presence of one single Cys in the paratope might lead to VHH dimers (50) whereby antigen binding is obstructed.
The IGHVH genes differ also from IGHV genes in a more subtle way. Apparently, the IGHVH genes-but not the IGHV genes-often contain peculiar sequences (i.e., palindromes or heptamer-like sequences of the Ig recombination signal sequence) that are recognized as unstable or prone to unequal DNA recombination, gene conversion, or gene replacement events (31). It has been hypothesized that such elements would lead to a faster gene evolution and thus to a faster expansion of the IGHVH repertoire (29). In addition, these elements might also be responsible for B-cell receptor editing (by a gene conversion mechanism with an IGHVH gene located upstream). Indeed, the cDNA sequence analysis of VHH with a known antigen specificity and retrieved after phage display very often reveals the sequences with an identical H3 loop (same V-D-J rearrangement) and with different H1 and/or H2 loop sequences, although it cannot be excluded that these binders were produced artificially by polymerase chain reaction (PCR) crossover.
BI82CH17-Muyldermans
Another surprising and subtle VHH sequence imprint has been introduced in the region encoding the H1 loop (31). In human and mouse VH sequences, this loop, bridging the two β-sheets of the V domain, contains conserved amino acids at positions 25, 27, 28, 30, and 39. These amino acids (Ala, Gly, Phe, Phe, and Met, respectively) are considered to be the key amino acids for the type 1 canonical loop structure (51) . In the VHH germ line genes, they are conserved with one notable difference, that is, the Phe28 and Ph30 (TTT and TTC codons) were replaced by Tyr codons (TAT and TAC). It has been reported that TAY base steps are hot spots for somatic hypermutation (i.e., are more prone to diversify), and indeed, these codons are very often mutated in affinitymatured VHH domains (31, 43). In addition, this codon mutagenesis is the main contributor to the extension of the HV region in the H1 loop toward the N-terminal loop region, and the H1 loop structure often deviates from the known canonical structures observed in human or mouse VH (52).
Promiscuous VH Genes Contribute to the VHH Repertoire
An antigen-binding site formed by two domains, which are first assembled independently by V-(D-)J gene recombinations and then combined, leads to a seemingly unlimited number of possible paratope structures and thus to a fitter immune system based on a minimal number of gene elements. It is surprising that HCAbs that lack the VH-VL combinatorial diversification can compete with conventional antibodies. The structural repertoire of the VHH paratope was even more restricted than originally anticipated when it was shown that two VHHs raised in two different dromedaries (in Morocco and in the United Arab Emirates immunized with the same antigen at different times) were assembled from different IGHVH genes and different J minigenes but from the same D element (53) . In addition, it was shown that the loop region encoded by the D element in the two VHHs adopted the same structure and interacted with the same epitope. However, the J and V gene elements apparently underwent convergent somatic hypermutations. This finding underscores the strength and importance of somatic hypermutations and selection during the affinity maturation of these antibodies.
The number of available VH (or VL) families is another contributor to possible paratope diversity. Up to a few years ago, all IGHVHs were reported to belong to IGHV3 family, the most abundant and widespread family in human and mouse genomes, and used for most versatile, functional antibodies (18) . However, recently the occurrence of VH germ lines of IGHV1 and of IGHV4 (clan II) were identified in alpaca (43). These genes were reported to produce a VH domain for conventional antibodies. The IGHV4 genes are also present in dromedary, where these V elements are surprisingly promiscuous as they can produce VH domains and VHH domains, the autonomous domains that function in antigen binding in HCAbs in absence of a VL partner (54) . These VH-like single domains with an IGHV4 imprint had a slightly lower hydrophobicity profile in their FR3.
Likewise, the IGHV3 genes (with a hydrophobic GLEW motif in FR2) are also found to produce HCAbs (without a CH1 domain). Therefore, the IGHV3 genes with a GLEW motif in camelids might be promiscuous as well and might function after V-D-J rearrangement and expression either paired with a VL in a conventional antibody or autonomously in an HCAb. Indeed, multiple antigen-binding VH-like domains with a GLEW motif have been isolated repeatedly from HCAb libraries. Sometimes, these VH-like domains clearly have a sequence imprint that prevents an association with a possible VL as they lack the conserved Trp118. The Trp118 is encoded by the J element (Figure 2) , is 100% conserved in human and mouse VHs, and is strongly involved in the VH-VL interaction (20 Changes may still occur before final publication online and in print 
Heavy-Chain Antibody Ontogeny
The occurrence of an IgM stage in an HCAb format is another enigma. Actually, we do not know how the class switch from an IgM to IgG occurs if an IGHVH gene is rearranged in the pre-B cell. Our best guess, and current working hypothesis, is that a rearranged IGHVH-D-
J (or an IGHV-D-J
* where J * indicates that the conserved Trp118 codon has been modified) might fail to be expressed on the surface of the pre-B cell in combination with the surrogate L chain, a dimer of VpreB and λ5 (55) . Normally, in the pre-B cell, it is suggested that after the IGHVH-D-J rearrangement, the unfolded CH1 of the VHH-IGMH translation product associates with the BiP protein and is retained in the endoplasmic reticulum (56) .This BiP protein should be exchanged by the surrogate L chain (where λ5 functions as a CL and VpreB as a VL) before the L chain has been rearranged for surface expression of the H chain and for pre-B-cell receptor signaling. Failure of the VpreB to associate with the VH domain will interfere with proper exposure of the pre-B-cell receptor and its signaling, causing the B cells to rapidly disappear (57), although escape routes might be in place. Where cells blocked in the surface expression of the pre-B-cell receptor are normally ablated, in camelids they might be rescued by an immediate class switch from IGHM to one of the dedicated IGHG genes for HCAbs. 
BIOCHEMICAL PROPERTIES OF NANOBODIES
Identification of Antigen-Specific Nanobodies
Nbs, the recombinant single variable domains derived from camelid HCAbs, are generally readily obtained after a brief immunization, followed by cloning the V gene repertoire from peripheral blood lymphocytes and by selection through phage display (58) . Antigen-specific HCAbs are affinity matured during a short immunization step, mostly with proteins as the immunogen but also by a DNA-prime, proteinboost strategy (59) . Because the entire antigenbinding fragment of the HCAb consists of one VHH domain, encoded by a gene fragment of only ∼360 bp that is easily amplified by PCR in one single amplicon, small libraries of ∼10 6 individual transformants are already representative of the immune VHH repertoire of B cells present in a blood sample of ∼50 ml. In cases where immunization is not practical (i.e., no available, toxic, or nonimmunogenic molecules), immune VHH libraries can be substituted by naive, semisynthetic, or synthetic V repertoires (60, 61) , but such libraries need to be much larger (∼10 9 individual clones) to allow the retrieval of high-affinity binders.
Antigen-specific Nbs are retrieved from immune or other libraries by phage display or any other selection protocol, including bacterial display, yeast display, intracellular 2 hybrid selection (62, 63) , ribosome display (64), and others. However, because of the robustness of the technology, the cloned V library is expressed preferably on a phage and panned on an antigen that is immobilized in wells of microtiter plates by passive adsorption, or when the antigen is biotinylated on streptavidin-coated solid supports (65) . Normally, two to three rounds of panning are sufficient to enrich the clones so that individual clones can be screened for production of antigen-specific Nbs in a standard enzyme-linked immunosorbent assay (ELISA). Nucleotide sequencing of the ELISApositive clones is used to deduce the amino acid sequence of the Nb. The entire procedure to identify useful antigen binders is fast as multiple immunogens or even proteome fractions can be used to immunize one animal in less than two months (66, 67) . In this way, the immune library can be used to select binders to various antigens in parallel. Thus, Nbs against hundreds of antigens can be identified each year by one researcher.
Affinity Parameters of Nanobodies
In contrast to the cloning of a scFv, whereby the VH and VL pairs that were affinity matured in B cells became scrambled by random assembly of the VH exons and VL exons that were first individually PCR amplified, the PCR amplification and cloning of the VHH present in one exon allowed the cloning of intact, affinity-matured VHH from peripheral B lymphocytes as a whole. Therefore, the antigen specificity and affinity of Nbs from immune libraries are of good quality. Kinetic k on and k off rate constants in the ranges of 10 5 to 10 6 M −1 s −1 and 10 −2 to 10 −4 s −1 , respectively, are routinely obtained so that low nanomolar or even picomolar equilibrium dissociation constants are obtained. Such affinity parameters are excellent for most applications. Nevertheless, in vitro affinity maturation approaches, such as error-prone PCR, spiked mutagenesis combined with ribosome display (68) and Ala scanning-based mutations to identify the critical amino acids for antigen recognition have been successfully introduced to improve the stability of the domain and/or the affinity for their cognate antigen (69) . In an alternative approach, a few carefully selected mutations at the edge of the paratope were introduced to measure their effect on antigen-Nb kinetic and equilibrium affinity values. These data were combined with a multivariate analysis of the parameterized quantitative descriptors of the mutations and buffers to propose a quantitative predictive algorithm that models the affinity parameters of all other possible mutants at those positions (70) .
Expression of Recombinant Nanobodies
The Nbs are expressed to a high level in microorganisms (71) (72) (73) , mammalian cell lines, and plants (74) . For bacterial expression, cloning the Nb after a secretion signal is preferred so that it is produced in the periplasm, where the oxidizing environment forms disulfide bonds properly. The purification is straightforward because Nbs are usually cloned in frame with an His6 tag so that, after periplasmic extraction (which already avoids major contaminations with cytoplasmic proteins), immobilized metal affinity chromatography and a gel filtration produce pure Nbs. Yields of several milligrams per liter of culture are routinely obtained from simple culture flasks. For applications where Nbs without any tags are required, it is recommended to select Nbs that bind to protein A. Most VHHs are closely related to members of human VH family 3, and such proteins are often retained on this affinity adsorbent (75) .
Stability of Nanobodies
Nbs are easily concentrated by ultrafiltration (with filters of mol wt cutoff <5,000) to 1-10 mg/ml −1 in standard phosphate or Tris buffers for usage as a stock solution. The shelf life of Nbs is excellent; they are stored for months at 4
• C, and even longer at −20 • C while maintaining full antigen-binding capacity. Incubations at 37
• C for several weeks seem to be tolerated as well (76) . Moreover, Nbs are robust under stringent conditions and resist chemical and thermal denaturation. Usually Nbs denature ∼2.3-3.3 M guanidinium at ∼60-80
• C (77). Some Nbs express an unusually stable behavior, resist temperatures above 90
• C (78), and have a chemical stability of 60 kJ/mol −1 (62, 77) . The stability of a Nb can be increased by introducing Cys at position 54 and 78 (on the C and E strands, respectively) to form an extra disulfide bond (79, 80) . These disulfide bondstabilized Nbs turn out to be highly resistant to degradation by pepsin or chymotrypsin (81) , suggesting that such Nbs can be administered orally. Trypsin-resistant Nbs for oral delivery have been obtained after random mutagenesis through DNA shuffling and selection for trypsin-resistant variants (82) . Furthermore, pannings with phage-displayed VHHs have been performed under harsh conditions (e.g., in presence of detergents or denaturants), and there were indications that such selected VHHs are also resistant to other denaturing conditions, such as high urea concentrations (83) . The high-temperature and acid tolerance of the filamentous phage has also been exploited to select for sdAbs with enhanced resistance or reversible refolding capacity upon returning to physiological conditions (84, 85) .
Because the Nb sequence (VHH family 3) is rather conserved, the scaffold of some highly stable Nbs have been used successfully to graft the antigen-binding loops of less-stable antigen-specific Nbs to obtain a chimeric Nb with the stability of the loop acceptor Nb and the antigen-specificity of the loop donor Nb (86) . However, this strategy is not always realistic, as much of the Nb stability is dictated by the CDR3 sequence (87) . Therefore, grafting CDR3 loops will also transfer their intrinsic contribution to stability. In addition, inasmuch as the CDR3 amino acids are either in direct contact with the antigen or they maintain and influence the conformation of the CDR3 amino acids that directly contact the antigen, the CDR3 amino acids responsible for reduced stability cannot be replaced without serious loss of affinity (88) .
Nanobodies Are Nonimmunogenic
The small size, stable behavior, rapid clearance from blood, and a sequence sharing a high degree of identity with human VH are all properties that predict low immunogenicity of a Nb. Indeed, no immune response against the Nb moiety was raised in mice or humans that were injected with Nb-containing constructs (89) (90) (91) . Moreover, a strategy was developed to humanize 12 out of the 14 amino acids that differ between human VH and camelid VHH (92) .
Recognition of Unique Epiopes by Nanobodies and Multivalent and/or Multispecific Constructs
The unique (convex) paratope architecture of sdAbs prefers to associate with concave surfaces of the antigen of sdAbs, such as the active site of an enzyme. Therefore, it is no surprise that many Nbs affect the catalytic activity of enzymes (10, (93) (94) (95) . Where some of the Nbs clearly behave as allosteric inhibitors (96, 97) , others might activate enzymatic activity (98) possibly as they stabilize the enzyme in an open conformation.
The strict monomeric behavior of the Nb in combination with its minimal size makes it an ideal building block to develop multidomain constructs (99) . Several dimeric Nb constructs have been identified: (a) the bivalent, monospecific construct whereby the product of tandemly cloned, identical Nbs increases the functional affinity (avidity) for the antigen; (b) the biparatopic, monospecific construct obtained by tandem cloning of two Nbs recognizing different epitopes on the same antigen, which possibly chelates the antigen and concomitantly binds with higher avidity (100); and (c) the bispecific construct generated by formation of a tandem pair of Nbs with each recognizing a different antigen, a process used to tether two independent antigens (101, 102) . In an alternative approach, the Nb is cloned to a protein moiety with a natural tendency to dimerize or to multimerize, such as a leucine zipper motif or the pentamerizing motif of verotoxin (103, 104) . Furthermore, the antigen-specific Nb gene has been cloned in frame with the hinge, CH2 and CH3 exons of human, and mouse or pig IgG and subsequently transfected in myeloma cell lines to reconstruct chimeric HCAbs (104, 105) .
APPLICATIONS WITH NANOBODIES
A renewable (or sustainable) source, economic production, small size, human(-ized) sequence, stable and soluble behavior in aqueous solutions, reversible refolding, and specific and high affinity for only one cognate target are the ideal properties for a practical binder. Normally, the Nbs selected from immune libraries meet all these requirements without the need for additional improvements. The notions that Nbs might recognize epitopes that are not antigenic for conventional antibodies and that many of them modulate the function of the target are supplementary assets. Obviously, these beneficial properties stimulated several research groups in universities and pharmaceutical and biotech companies to employ Nbs as a research tool and/or to develop future diagnostic and therapeutic applications. This resulted in numerous applications whereby the proof of principle has been successfully demonstrated; the applications have been covered recently elsewhere (106) (107) (108) . Here, we focus on a number of examples wherein Nbs offer a special advantage over other equivalent binders and where Nbs surpass the "me-too" qualification.
Nanobodies as Research Tools
The fast retrieval of high-affinity binders to various targets with the Nb identification technology permits the assembly of a comprehensive resource of well-characterized reagents for important targets, including intracellular signaling molecules and cancer biomarkers, as versatile tools in this postgenomic era (109).
The genetic fusion of a fluorescent protein with a Nb, and its intracellular expression, produces useful chromobodies or fluobodies to trace the antigen in various cellular compartments in living cells (110, 111) . Moreover, the use of GFP-binding Nbs coupled to organic dyes on any GFP-tagged construct enabled single-molecule localization with superresolution imaging techniques (112). The specificity of a Nb for particular conformational variants of its target and its capacity to induce and report conformational changes have been exploited for monitoring by ratio imaging target protein expression, its translocation, and final subcellular localization (35, 113-115) . In parallel research, it has been confirmed that intracellularly expressed sdAbs remain soluble and exhibit specific antigen recognition activities to abrogate particular protein functions of the antigen inside cells. The identification of such sdAbs, which compete with normal in situ protein-protein interactions, provides a tool for target validation and a lead molecule to investigate difficult interactions or interactions considered undruggable (116, 117) .
Apart from blocking a surface of the target protein to interfere with proper protein-protein interactions, it is also possible to trigger the depletion of antigen via the ubiquitin pathway. Proof of this concept was given in Drosophila melanogaster and Danio rerio models by intracellular expression of the GFP-specific Nbs fused to the F-box domain to recruit polyubiquitination machinery and to initiate the proteasomemediated degradation of the target, captured in the ubiquitinated Nb complex (118).
Several years ago, antibodies were proposed to assist the crystallization process and structural determination of flexible or aggregating ' "high-hanging fruit" proteins. Apart from a few isolated cases, it is only now that rapid progress has been made because of the availability of recombinant single-domain affinity reagents. These affinity reagents fix highly dynamic proteins in a binder-preferred conformation and stabilize the intrinsic flexible regions or detergent-solubilized membrane proteins by shielding hydrophobic antigen surfaces from contact with solvent to allow the formation of effective crystal contacts (119). Again, it is the fast identification of antigenspecific Nbs as well as the high-production yields, small size, robust structure and targeting clefts on the surface of the antigen (which often coincide with active enzymatic sites or ligand-or receptor-binding cavities) that allow Nbs to tackle the crystallization and structural determination of these challenging targets (120-123).
Nanobodies as Diagnostic Tools
The development of Nbs for the quantitative detection or the simple capture of their targets has been surprisingly slow. The larger size of the conventional antibodies is probably better suited for random coupling to solid surfaces. However, the availability of high-affinity Nbs that are easily modified to avoid chemically reactive groups (primarily amines from lysines) in the vicinity of the paratope and the inclusion of such groups at the opposite end of the domain that permit their directional immobilization on the sensor surface for the maximal capturing capacity of the antigen. This allowed the use of Nbs to generate sensitive and selective biosensors (124).
In another setting, Nbs were conjugated chemically to branched gold nanoparticles to produce an effective antigen-targeting photothermal therapeutic upon irradiation with laser light in the near biological window (125).
The fusion of the Nb gene with the gene for the magnetosome protein MamC and expression in the magnetite-synthesizing Magnetospirillum gryphiswaldense bacteria offer an elegant strategy for producing Nbs directly coupled to magnetic nanoparticles (126) to capture and enrich analyte at low concentrations in complex mixtures. The covalent linkage of Nbs to a solid, inert, or magnetic support seems to be a highly valued approach to generate affinity adsorbents. This was shown by developing the nanotrap, an immobilized Nb that recognizes the GFP as a target (115), and by Nbs directed against various immunoglobulin isotypes (127). Such affinity adsorbents have been commercialized by ChromoTek GMbH (Planegg-Martinsried, Germany) and BAC BV (Naarden, Netherlands), respectively. The latter company recently introduced a tag-binding Nb to their portfolio. This Nb specifically recognizes the C-terminal tetraamino acids Glu-Pro-Glu-Ala (EPEA) (128) that can be cloned as a tag behind any protein. The small size of Nbs means that few proteins from a complex mixture in an extract will recognize the sdAb, and this significantly reduces the nonspecific adsorption of molecules.
Owing to their small size, which is well below the renal clearance cutoff of mol wt ∼50,000, Nbs are rapidly eliminated from blood, and this is exactly what is required for a good in vivo-imaging agent (129). Rapid targeting to diseased tissue and fast blood clearance make use of short-lived nuclides ( 68 Ga, 18 F) with half-life times (t1/2) of 68 and 110 min, respectively, which make positron emission tomography and computed tomography imaging practical for measuring picomolar concentrations of the tracer within 1-3 h postinjection and thus result in a very low radiation burden for the patient. This was recently tested in mice xenografts with Nbs against an epidermal growth factor receptor labeled with 68 Ga, yielding a tumor to blood ratio of 25 after 3 h (130) against HER-2, a breast cancer antigen (131), and V-CAM1, an antigen used to diagnose vulnerable atherosclerotic plaques (132) .
Nanobodies as Therapeutics
Antibodies have been used for ages for passive immunization to treat envenomed victims or infected patients. Although polyclonal antibodies generally result in better neutralization and thus better protection, a monoclonal Nb screened to recognize special epitopes involved in receptor recognition can reach an extremely high-neutralization potency (133) . In addition to scorpion toxins, several antibacterial toxins (134) and antisnake venom Nbs are actively being investigated (135) (136) (137) . Moreover, in some cases, the large size of conventional antibodies obstructs the access of hidden and essential epitopes on pathogenic agents, such as viruses, bacteria, or parasites; in such cases, Nbs will have special advantages as therapeutics (138) (139) (140) (141) (142) (143) (144) (145) (146) .
Several other Nb-derived therapeutics (e.g., anti-IL6R or anti-TNFα used to treat inflammatory diseases, an anti-von Willebrand factor used to treat patients with acute thrombotic thrombocytopenic purpura, as well as an anti-RANKL used to combat bone loss disorders, and others) are in the pipeline; some have passed phase I and phase II tests (147) . However, the competition from other therapeutic compounds is huge. The success of Nbs in therapy will come from a more patient-friendly administration (topical, oral, or inhalation) and from obtaining improved blood levels over a prolonged time, as well as by fine-tuning the residence time, by linking the Nb to albumin-binding moieties, or by changing their hydrodynamic volume in various ways (148) .
In addition, the added value of affinitymatured Nbs originates from their capacity to discriminate the cognate target from closely related variants; such high specificity often cannot be achieved by most small organic antagonists. Therefore, Nbs have been exploited to block unwanted enzymatic activities, e.g., the cytotoxic effects of T-cell ecto-ADPribosyltransferase ART2.2 in lymphatic organs (59) .
Finally, Nbs have also been assessed in their capacity to deliver cargoes to tissues that are difficult to access. To this end, Nbs were generated that cross the blood-brain barrier or that lead to transcytosis across epithelia (100, (149) (150) (151) .
SUMMARY POINTS
1. An accessible and streamlined protocol has been developed for the fast generation of several Nbs that recognize with high specificity and high affinity their cognate antigen. Recombinant Nbs are well expressed in a variety of microorganisms, highly robust, and easy to engineer according to the needs of the user or for optimal performance in the envisaged application.
2. Multiple crystal structures of Nbs in complex with their antigen are available. These provide detailed insight that supports rationally designed engineering to increase the potency of Nbs.
3. It is well established that Nbs prefer to interact with cavities on the surface of their antigen, such as the catalytic site of enzymes or the ligand-binding site of receptors. Therefore, many Nbs exert an inhibiting, agonistic, or antagonistic effect on their antigen.
4. Targets that switch rapidly between different conformations can be trapped and stabilized in the conformation that is preferred by Nbs. This leads to the identification of unknown conformations and allows detailed investigation of, for example, enzyme mechanisms. Nbs might stabilize otherwise unstable proteins and prevent amyloidosis.
5. The strict monomeric behavior of Nbs makes them a perfect tool to include in larger constructs where the Nb provides antigen specificity and the targeting function.
6. Nbs seem successful as crystallization chaperons. Several membrane proteins and unstable proteins that are prone to degradation, unfolding, or aggregation have been stabilized with Nbs, and an impressive number of crystal structures of such high-hanging fruit proteins have been determined in the past years.
7. The availability of techniques for radiolabeling Nbs in conjunction with their small size, which is well below the renal cutoff, makes them ideal tools for noninvasive in vivo imaging.
FUTURE ISSUES
1. Conventional antibodies and HCAbs are elicited upon immunization with antigens. However, occasionally the response in the HCAb is disappointingly low (for example, small peptides and haptens). Therefore, better knowledge about the effects of adjuvants on the immune system of camelids is necessary. Moreover, developing a clear picture of the different HCAb isotypes (subisotypes and allotypes) occurring in sera and the exact function and role of each of these subisotypes is high priority.
2. The ontogeny of functional HCAbs in B cells of camelids remains a black box. Although the majority of genes have been identified, we do not understand how and why the V-D-J rearrangement involving an IGHV3H gene has a longer CDR3 or how and when the class switch from IGHM to IGHG2 or IGHG3 occurs. In addition, any information on the involvement and role of the surrogate L chain at the pre-B-cell stage would be welcome.
3. The toolbox of Nb-based products needs further development for target validation and to facilitate cutting-edge science. We expect additional developments for Nbs as highly specific capturing agents; in chromatin immunoprecipitations; in intracellular imaging; and in specific degradation, retention, or translocation of intracellular targets.
4. Investigators need to implement Nbs in the development of phenotypic selection strategies to obtain target-modulating Nbs.
5. It is expected that Nbs will be generated that create access to unique locations, such as those that cross the blood-brain barrier or that could deliver a cargo to particular cells and penetrate their cell membrane. Some of these objectives could be reached by equipping lentiviral or adenoviral vectors with Nbs.
6. The development of a Nb in a next-generation therapeutic and its commercialization are anticipated.
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